Centogene N.V. (CNTG)
Pre-market:
| Previous close | 0.4710 |
| Open | 0.4700 |
| Bid | 0.3220 x 200 |
| Ask | 0.5980 x 200 |
| Day's range | 0.4508 - 0.4700 |
| 52-week range | 0.4508 - 2.5200 |
| Volume | |
| Avg. volume | 50,788 |
| Market cap | 12.846M |
| Beta (5Y monthly) | -0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notice
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth in
- GlobeNewswire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs). Under
- GlobeNewswire
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than ExpectedCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the publication in Science of research on human pre-T cell receptor alpha (pre-TCRα) deficiency, a condition that often results in infection, lymphoproliferation, a
